These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 6376009)
21. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Heinemann L; Linkeschova R; Rave K; Hompesch B; Sedlak M; Heise T Diabetes Care; 2000 May; 23(5):644-9. PubMed ID: 10834424 [TBL] [Abstract][Full Text] [Related]
22. Mixtures of human intermediate and human regular insulin in type 1 diabetic patients. Evaluation of free insulin levels and insulin action on glucose metabolism after combined and separate subcutaneous administration. Klauser R; Schernthaner G; Prager R Diabetes Res Clin Pract; 1988 Sep; 5(3):185-90. PubMed ID: 3065016 [TBL] [Abstract][Full Text] [Related]
23. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Roach P; Woodworth JR Clin Pharmacokinet; 2002; 41(13):1043-57. PubMed ID: 12403642 [TBL] [Abstract][Full Text] [Related]
24. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes. Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561 [TBL] [Abstract][Full Text] [Related]
25. [Clinical experiences with the substitution of biosynthetic human insulin in children and adolescents with type I diabetes]. Hürter P; von Schütz W; Zick R; Stolzenbach K Monatsschr Kinderheilkd; 1985 May; 133(5):277-83. PubMed ID: 3892270 [TBL] [Abstract][Full Text] [Related]
26. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Rosenstock J; Park G; Zimmerman J; Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511 [TBL] [Abstract][Full Text] [Related]
27. Intermediate-acting insulin preparations: NPH and lente. Deckert T Diabetes Care; 1980; 3(5):623-6. PubMed ID: 7192205 [TBL] [Abstract][Full Text] [Related]
28. The plasma glucose response of normal fasting subjects to neutral regular and NPH biosynthetic human and purified pork insulins. Galloway JA; Spradlin CT; Root MA; Fineberg SE Diabetes Care; 1981; 4(2):183-8. PubMed ID: 7011723 [TBL] [Abstract][Full Text] [Related]
29. Comparison of the activity and pharmacokinetics of porcine insulin and human insulin (Novo) as assessed by the glucose clamp technique in normal and diabetic man. Home PD; Shepherd GA; Noy G; Massi-Benedetti M; Hanning I; Burrin JM; Alberti KG Diabetes Care; 1983; 6 Suppl 1():23-8. PubMed ID: 6343033 [TBL] [Abstract][Full Text] [Related]
30. Absorption, effectiveness and side effects of highly purified porcine NPH-insulin preparations (Leo). Kølendorf K; Aaby P; Westergaard S; Deckert T Eur J Clin Pharmacol; 1978 Nov; 14(2):117-24. PubMed ID: 363432 [TBL] [Abstract][Full Text] [Related]
31. A comparison of the pharmacokinetics and metabolic effects of human regular and NPH insulin mixtures. Davis SN; Thompson CJ; Brown MD; Home PD; Alberti KG Diabetes Res Clin Pract; 1991 Aug; 13(1-2):107-17. PubMed ID: 1773708 [TBL] [Abstract][Full Text] [Related]
32. The action profiles of human NPH insulin preparations. Starke AA; Heinemann L; Hohmann A; Berger M Diabet Med; 1989 Apr; 6(3):239-44. PubMed ID: 2523785 [TBL] [Abstract][Full Text] [Related]
33. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes. Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975 [TBL] [Abstract][Full Text] [Related]
34. Semilente-insulin at bedtime is superior to NPH-insulin for the suppression of the dawn-phenomenon in adolescents with type-I-diabetes. Holl RW; Teller WM; Heinze E Exp Clin Endocrinol Diabetes; 1996; 104(5):360-4. PubMed ID: 8957270 [TBL] [Abstract][Full Text] [Related]
35. Absorption kinetics and action profiles of mixtures of short- and intermediate-acting insulins. Heine RJ; Bilo HJ; Fonk T; van der Veen EA; van der Meer J Diabetologia; 1984 Dec; 27(6):558-62. PubMed ID: 6397384 [TBL] [Abstract][Full Text] [Related]
36. Comparison of insulin levels after injection by jet stream and disposable insulin syringe. Malone JI; Lowitt S; Grove NP; Shah SC Diabetes Care; 1986; 9(6):637-40. PubMed ID: 3542456 [TBL] [Abstract][Full Text] [Related]
37. [Action profile of human ultralente insulin compared with human NPH-insulin]. Starke AA; Heinemann L; Hohmann A; Berger M Dtsch Med Wochenschr; 1989 Apr; 114(16):618-22. PubMed ID: 2651061 [TBL] [Abstract][Full Text] [Related]
38. The pharmacokinetics of subcutaneous regular insulin in type I diabetic patients: assessment using a glucose clamp technique. Gardner DF; Arakaki RF; Podet EJ; Nell LJ; Thomas JW; Field JB J Clin Endocrinol Metab; 1986 Sep; 63(3):689-94. PubMed ID: 3525600 [TBL] [Abstract][Full Text] [Related]
39. Biosynthetic human insulin: pharmacokinetics and effects in healthy human volunteers. Brogard JM; Blickle JF; Pinget M; Stahl A; Dorner M Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):575-80. PubMed ID: 6360919 [TBL] [Abstract][Full Text] [Related]
40. Porcine and human insulin absorption from subcutaneous tissues in normal and insulin-dependent diabetic subjects: a deconvolution-based approach. Nosadini R; De Kreutzenberg S; Duner E; Iori E; Avogaro A; Trevisan R; Fioretto P; Doria A; Merkel C; Cobelli C J Clin Endocrinol Metab; 1988 Sep; 67(3):551-9. PubMed ID: 3045144 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]